Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refracto
A phase 3 trial of Dabrafenib, Trametinib in thyroid cancer, run by Novartis Pharmaceuticals, active and no longer recruiting.
Overview
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer is a phase 3 interventional study registered as NCT04940052 by Novartis Pharmaceuticals, with 153 participants enrolled, started 2021-11-15 and due to reach its primary completion in 2025-01-22. Interventions recorded: Dabrafenib, Trametinib, Trametinib Placebo, Dabrafenib placebo. Conditions listed: Differentiated Thyroid Cancer (DTC). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
Shares Trametinib, Novartis.
- TrialCOMBI-AD
Shares Dabrafenib, Trametinib.
- TrialPlatform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
Shares Trametinib, Novartis.
- TrialRollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other
Shares Trametinib, Novartis.
- PathwayThyroid cancer (KEGG map)
Shares Dabrafenib, Trametinib, Thyroid cancer.
- PathwayMelanoma (KEGG map)
Shares Dabrafenib, Trametinib.
- TreatmentDabrafenib + trametinib
Shares Dabrafenib, Trametinib, Novartis, Thyroid cancer.
- PathwayGlioma (KEGG map)
Shares Dabrafenib, Trametinib.